The gene encoding methylthioadenosine phosphorylase (MTAP) is expressed in normal tissues but 10 to 15% of tumors present deletions of MTAP expression that lead to accumulation of its metabolite 5-methylthioadenosine (MTA). Previous research has shown that selective inhibition of protein arginine methyltransferase 5 (PRMT5) in the presence of MTA may be considered a potential therapeutic strategy for the treatment of MTAP-deleted cancer.
The University of Texas System has synthesized mitogen-activated protein kinase 1 (MAPK1; ERK2) inhibitors reported to be useful for the treatment of cancer.
In the year’s fourth-largest deal, Prime Medicine Inc. will collaborate with Bristol Myers Squibb Co. in a research collaboration and license agreement totaling $3.61 billion. The two companies plan to develop reagents for ex vivo T-cell therapies. While the programs and targets have yet to be disclosed, BMS is expanding its CAR T development, begun more than five years ago, with this deal.
Synnovation Therapeutics Inc. has identified Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
Uereka Biosciences Inc. has synthesized mitogen-activated protein kinase kinase kinase 13 (MAP3K13; LZK) inhibitors reported to be useful for the treatment of cancer.
Spima Therapeutics SAS has announced its launch with a focus on developing innovative peptide-based immunotherapies for difficult-to-reach targets, especially protein-protein interactions.
Cartherics Pty Ltd. has raised over its target of AU$15 million (US$10.3 million) in an oversubscribed private financing round. Funding will support a clinical trial for CTH-401, the company’s lead cell therapy for ovarian cancer, and expand its pipeline to include other diseases.
RSS
